Avidity Biosciences Inc (NASDAQ:RNA) has a beta value of 0.91 and has seen 1.45 million shares traded in the last trading session. The company, currently valued at $5.20B, closed the last trade at $44.82 per share which meant it gained $2.95 on the day or 7.05% during that session. The RNA stock price is -13.3% off its 52-week high price of $50.78 and 88.76% above the 52-week low of $5.04. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.71 million shares traded. The 3-month trading volume is 1.30 million shares.
The consensus among analysts is that Avidity Biosciences Inc (RNA) is Buy stock at the moment, with a recommendation rating of 1.09. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.71.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Sporting 7.05% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RNA stock price touched $44.82 or saw a rise of 1.86%. Year-to-date, Avidity Biosciences Inc shares have moved 395.25%, while the 5-day performance has seen it change -1.97%. Over the past 30 days, the shares of Avidity Biosciences Inc (NASDAQ:RNA) have changed -5.24%. Short interest in the company has seen 14.88 million shares shorted with days to cover at 8.98.
Wall Street analysts have a consensus price target for the stock at $54.5, which means that the shares’ value could jump 17.76% from current levels. The projected low price target is $50.0 while the price target rests at a high of $59.0. In that case, then, we find that the current price level is -31.64% off the targeted high while a plunge would see the stock gain -11.56% from current levels.
Avidity Biosciences Inc (RNA) estimates and forecasts
Figures show that Avidity Biosciences Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 70.22% over the past 6 months, with this year growth rate of -1.03%, compared to 17.50% for the industry. Revenue growth from the last financial year stood is estimated to be 18.60%.
8 analysts offering their estimates for the company have set an average revenue estimate of 4.27M for the current quarter. 8 have an estimated revenue figure of 2.39M for the next ending quarter. Year-ago sales stood 1.84M and 2.19M respectively for this quarter and the next, and analysts expect sales will grow by 132.10% for the current quarter and 18.60% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -57.60% over the past 5 years.
RNA Dividends
Avidity Biosciences Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
Insiders own 4.88% of the company shares, while shares held by institutions stand at 96.56% with a share float percentage of 101.52%. Investors are also buoyed by the number of investors in a company, with Avidity Biosciences Inc having a total of 300.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 16.16 million shares worth more than $660.1 million. As of 2024-06-30, FMR LLC held 18.5285% of shares outstanding.
The other major institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, with the holding of over 10.92 million shares as of 2024-06-30. The firm’s total holdings are worth over $445.94 million and represent 12.5173% of shares outstanding.
